Release date: 2024-08-19 15:34:18 Article From: Lucius Laos Recommended: 133
Selpercatinib is a targeted drug designed for the treatment of non-small cell lung cancer, targeting RET gene mutations, and the mechanism of action is to limit the spread of cancer cells by inhibiting RET kinase, and is usually used in patients who do not respond to other treatments.
There are several important considerations to be aware of when treating with Selpercatinib.
Selpercatinib may cause retinal pigment epithelium detachment (RPED), with symptoms including blurred vision, floaters, etc. Routine monitoring (eg, optical coherence tomography) is not performed in clinical trials, but the asymptomatic incidence of RPED is unknown.
The use of Selpercatinib may cause hyperphosphatemia, resulting in calcification and calcium deposition of soft tissues and skin. An increase in phosphate levels is one of the side effects of the drug.
When using Selpercatinib, special populations need to pay special attention to the following medication guidelines.
Patients with severe liver impairment should reduce the dose of Selpercatinib according to their doctor's recommendation to reduce the side effects caused by the drug. For patients with mild to moderate hepatic impairment, dose adjustment is usually not necessary, but any adverse effects during treatment should be closely watched. If there is a change in the patient's liver function, the treatment regimen should be adjusted promptly.
The safety and efficacy of Selpercatinib in children under 12 years of age have not been fully validated. Extreme caution should be taken when using the drug in children, a detailed assessment should be carried out before treatment, carried out under strict supervision by a professional doctor, to avoid possible risks and adverse reactions.
It is important to be aware of the possible adverse effects of Selpercatinib, and here are some common side effects and considerations.
Symptoms of anemia include fatigue, dizziness, shortness of breath, etc., which may affect the patient's life. Your doctor may recommend iron or other nutrients and regular monitoring of your hemoglobin levels to manage anemia.
Constipation problems can cause patients to feel bloated and uncomfortable, affecting gastrointestinal function. Patients should increase their dietary fiber intake, drink plenty of water, and use laxatives as recommended by their doctors to promote normal bowel movements.
[Warm tips] If you experience any discomfort during the use of Selpercatinib, please contact your doctor for help.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: